Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

3.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

18.3K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
18.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

9.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.

Blood cancer journal·2026
Same author

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.

The New England journal of medicine·2024
Same author

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.

Blood·2024
Same author

Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma.

Blood advances·2024
Same author

Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.

Blood advances·2023
Same author

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.

Haematologica·2023

Related Experiment Video

Updated: Mar 29, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

B-cell receptor pathway modulators in NHL.

Kristie A Blum1

  • 1Division of Hematology, The Ohio State University, Columbus, OH.

Hematology. American Society of Hematology. Education Program
|December 6, 2015
PubMed
Summary
This summary is machine-generated.

New B-cell receptor (BCR) pathway inhibitors show promise for non-Hodgkin

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

22.2K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Related Experiment Videos

Last Updated: Mar 29, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

22.2K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib and phosphoinositide-3-kinase (PI3K) inhibitors like idelalisib have shown success in treating relapsed or refractory non-Hodgkin's lymphoma (NHL).
  • The B-cell receptor (BCR) pathway is a key target for novel therapies in NHL.
  • Numerous clinical trials are investigating new BCR pathway inhibitors, both as single agents and in combination therapies.

Purpose of the Study:

  • To review current data on single-agent and combination therapies using BCR inhibitors in NHL.
  • To discuss toxicities and resistance mechanisms associated with these agents.
  • To explore the future potential of BCR inhibitors, including their use in front-line settings for specific NHL subtypes.

Main Methods:

  • Systematic review of current clinical data on BCR inhibitors in NHL.
  • Analysis of efficacy, safety, and resistance patterns.
  • Exploration of future therapeutic strategies and clinical trial outcomes.

Main Results:

  • Emerging data supports the efficacy of single-agent and combination BCR inhibitor therapies in NHL.
  • Common and serious toxicities are identified, requiring careful management.
  • Hypothesized resistance mechanisms are being investigated to optimize treatment.

Conclusions:

  • BCR inhibitors represent a significant advancement in NHL treatment, offering new therapeutic options.
  • Understanding and managing toxicities and resistance are crucial for successful clinical application.
  • Further research may establish BCR inhibitors as front-line treatments for selected NHL subtypes.